Lupus Nephritis
Starting with higher-dose prednisone boosts 1-year renal response in lupus nephritis
An initial median prednisone dose of 45 mg per day achieved significantly better complete renal response rates at 1 year in patients with new-onset lupus nephritis, according to data published in Arthritis Care & Research.
Targeted B-cell therapy effective in lupus nephritis without immunosuppression
An intensified B-cell depletion induction therapy without maintenance immunosuppression was no less effective than standard of care for treating lupus nephritis, researchers found.
Anifrolumab, obinutuzumab show ‘promising results’ for lupus drug pipeline
Several emerging therapies for lupus have shown promising results in the past year, with anifrolumab and obinutuzumab potentially attracting FDA attention, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
Risk for atherosclerotic CVD in lupus nephritis ninefold higher with renal arteriosclerosis
Severe renal arteriosclerosis is associated with a nine times greater risk for atherosclerotic cardiovascular disease in patients with lupus nephritis, according to data published in Arthritis Care & Research.
FDA approves Lupkynis, first-ever oral therapy for lupus nephritis
The FDA has approved voclosporin as the first oral treatment for lupus nephritis in adult patients who are receiving background immunosuppressive therapy, according to a press release from Aurinia Pharmaceuticals.
FDA approves Benlysta, first treatment for lupus nephritis
The FDA has approved belimumab in intravenous and subcutaneous formulations for the treatment of lupus nephritis in adult patients who are receiving standard therapy, according to a press release from GlaxoSmithKline.
Survey shows education and communication gaps about lupus nephritis
Belimumab plus standard therapy boosts renal outcomes, reduces steroids in lupus nephritis
Adding belimumab to standard therapy improves renal outcomes, biomarker levels and overall disease activity among patients with lupus nephritis, according to a speaker at ACR Convergence 2020.
NOBILITY: Gazyva sustains safety, efficacy against lupus nephritis over 2 years
Obinutuzumab provides sustained clinical benefit through 2 years among patients with lupus nephritis, with treatment efficacy maintained 18 months after the final infusion, according to data presented at ACR 2020.
Belimumab plus standard therapy superior to standard therapy alone for lupus nephritis
A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard therapy alone in patients with lupus nephritis, according to data published in the New England Journal of Medicine.